Ciprofolxacin Injectable (IV) bulk supplier for pharma manufacturers

Ciprofolxacin Injectable (Iv) 200 mg/100 mL, 400 mg/200 mL Suppliers & Bulk Manufacturers

Available Forms: Injectable (IV)

Available Strengths: 200 mg/100 mL, 400 mg/200 mL

Reference Brands: Cipro(US & EU)

Ciprofloxacin IV inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and leading to bacterial cell death. It provides rapid, broad-spectrum activity against severe infections such as sepsis and pneumonia. Benefits include high tissue penetration, quick onset, and effective treatment of serious bacterial infections in hospital settings.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ciprofolxacin Injectable (Iv)? List it or send an offer →

Product Description: Ciprofloxacin IV is approved in the EU and US for severe bacterial infections, including sepsis, pneumonia, and complicated urinary tract infections. In the EU, brands like Cipro are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for ciprofloxacin IV, ensuring adherence to European and US standards for safe, effective treatment of serious bacterial infections.

Ciprofolxacin Injectable (Iv) — third party manufacturing & bulk supply

Ciprofolxacin Injectable (Iv) 200 mg/100 mL, 400 mg/200 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ciprofolxacin Injectable (Iv) is supplied as Injectable (IV) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ciprofolxacin Injectable (Iv) listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ciprofolxacin Injectable (Iv) →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Ciprofolxacin Injectable (IV) is listed as Injectable (IV) in 200 mg/100 mL, 400 mg/200 mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ciprofolxacin Injectable (IV) is referenced against Cipro(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.